The Technical Analyst
Janone Inc [JAN]
Exchange: NASDAQ Sector: Industrials Industry: Waste Management
Janone Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
7.30% $3.97
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 34.12 mill |
| EPS: | -4.27 |
| P/E: | -0.930 |
| Earnings Date: | May 22, 2024 |
| SharesOutstanding: | 8.59 mill |
| Avg Daily Volume: | 0.301 mill |
| RATING 2024-04-19 |
|---|
| C- |
| Strong Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 4/22 | 2/23 | 3/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.930 | sector: PE 11.29 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.930 | industry: PE 59.77 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.175 (-104.41%) $-4.15 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.67 - 4.27 ( +/- 7.56%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-01-05 | Isaac Antonios | Buy | 125 787 | Common Stock |
| 2023-01-05 | Johnson Virland A | Buy | 78 617 | Common Stock |
| 2021-05-24 | Johnson Virland A | Sell | 32 933 | Common Shares |
| 2020-11-03 | Johnson Virland A | Sell | 1 469 | Common Stock |
| 2021-02-05 | Johnson Virland A | Sell | 4 112 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 96 transactions |
| Buy: 2 390 604 | Sell: 701 030 |
Forecast:
16:00 - $3.97
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.97
Forecast 2: 16:00 - $3.97
Forecast 3: 16:00 - $3.97
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.97 (7.30% ) |
| Volume | 0.157 mill |
| Avg. Vol. | 0.301 mill |
| % of Avg. Vol | 52.33 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For JAN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
JAN
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs; and designs, develops, and sells cellular transceiver modules and associated wireless services. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.
Latest Press Releases
2024-03-15 09:00:00 - Press Release
Janone Regains Compliance With Nasdaq's Listing Requirements
Las vegas, march 15, 2024 /prnewswire/ -- janone (nasdaq: jan), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, today announced that on march 13, 2024 it received a notification letter from the listing qualifications staff of the nasdaq stock market inc. ("nasdaq") indicating that the company had regained compliance with the minimum bid price requirement set forth in rule 5550(a)(2) of the nasdaq listing rules (the "minimum bid price requirement"). as previously announced, the company received a notification letter from nasdaq on september 11, 2023, indicating that the closing bid price per share had been below $1.00 for a period of 30 consecutive business days and that the company did not meet the minimum bid price requirement.
2023-09-21 11:30:00 - Press Release
Janone To Present At The Dawson James 8th Annual Investment Conference
Chief medical officer dr. amol soin will explain innovative approaches to pain management and janone's development of non-addicting treatments for pain las vegas , sept. 21, 2023 /prnewswire/ -- janone (nasdaq: jan), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the dawson james securities 8th annual investment conference in jupiter, florida.
2023-08-31 13:30:00 - Press Release
Janone To Present In Person And By Video At H.c. Wainwright's 25th Annual Global Investment Conference
Chief medical officer dr. amol soin will discuss innovative approaches to pain management and janone's development of non-addicting treatments for pain las vegas , aug. 31, 2023 /prnewswire/ -- janone (nasdaq: jan), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the h.c. wainwright 25 th annual global investment conference in new york city.
2023-08-29 13:30:00 - Press Release
Janone Earns Us Patent For The Use Of Its Novel Formulation Of Low-dose Naltrexone, Jan123, To Treat Chronic Pain
The broad patent coverage is a major milestone for the commercial success of jan123 las vegas , aug. 29, 2023 /prnewswire/ -- janone (nasdaq: jan), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has earned a us patent for its innovative formulation of low-dose naltrexone, jan123, for treating pain. the broad patent coverage is a major milestone for the commercial success of jan123 jan123 is being developed to treat complex regional pain syndrome (crps), a rare and often life-altering condition characterized by severe pain and hypersensitivity to touch.
2023-08-25 14:30:00 - Press Release
Janone Wins "best Abstract" Award At The Ohio Society Of Interventional Pain Physicians Annual Meeting
Abstract explained jan101's statistically significant reduction in pain and improvement in nerve conduction velocity in prior phase ii study. las vegas , aug. 25, 2023 /prnewswire/ -- janone (nasdaq: jan), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, has won a prestigious "best abstract" award for reporting that janone's treatment for diabetic neuropathy showed both effectiveness against pain and potential to improve nerve function.
Latest News
2023-11-09 08:05:00 - InvestorPlace
Why Is JanOne (JAN) Stock Up 40% Today?
JanOne (NASDAQ: JAN ) stock is on the rise Thursday despite a lack of news from the clinical-stage biopharmaceutical company. There haven't been any news press releases of filings with the Securities and Exchange Commission (SEC) from the company that would cause today's rally.
2023-09-21 11:30:00 - PRNewsWire
JanOne to Present at the Dawson James 8th Annual Investment Conference
Chief Medical Officer Dr. Amol Soin will explain innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Sept. 21, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the Dawson James Securities 8th Annual Investment Conference in Jupiter, Florida.
2023-08-31 13:30:00 - PRNewsWire
JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference
Chief Medical Officer Dr. Amol Soin will discuss innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Aug. 31, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the H.C. Wainwright 25 th Annual Global Investment Conference in New York City.
2023-08-18 12:42:00 - PRNewsWire
JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting
JAN101 Showed Statistically Significant Reduction in Pain and Improvement in Nerve Conduction Velocity in Prior Phase II study. LAS VEGAS , Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present prior data on Jan101's randomized double blind placebo-controlled trial in diabetic neuropathy patients.
2022-06-28 09:27:38 - PennyStocks
Penny Stocks To Watch: Why TOUR, JAN, ENDP, BRDS & WEJO Stock Are Moving
Penny stocks to watch with news The post Penny Stocks To Watch: Why TOUR, JAN, ENDP, BRDS & WEJO Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-06-07 15:20:36 - PennyStocks
Best Penny Stocks to Buy Now? 3 to Watch This Week
2022-06-07 10:38:02 - Benzinga
Why JanOne Shares Are Skyrocketing Today
JanOne Inc (NASDAQ: JAN) shares are trading higher by 42.40% at $3.56 after the company announced that a patent was issued that covers a method of improving nerve function using JAN101. JAN101 (formerly known as TV1001SR), is a potential treatment for peripheral artery disease (PAD), a.
2022-05-31 12:20:03 - Benzinga
Why JanOne Shares Are Trading Higher Today
JanOne Inc (NASDAQ: JAN) sold all of the assets, and none of the liabilities, of GeoTraq Inc., its wholly-owned subsidiary, to SPYR Inc (OTC: SPYR) for an aggregate of $13.5 million. The purchase price is payable in cash and shares of SPYR's common stock.
2021-12-16 15:10:31 - Benzinga
JanOne Subsidiary Gets $1.6M Recycling Contract In Virginia, North Carolina
JanOne Inc (NASDAQ: JAN) subsidiary ARCA Recycling, Inc. has received a contract to provide appliance recycling services to customers of a major electric utility in Virginia and North Carolina. The total value of the contract awarded is estimated to be ~$1.6 million.
2021-12-07 15:26:41 - Benzinga
JanOne Enters Option Agreement For Rights To Novel Strategy To Reduce Methamphetamine Use
JanOne Inc (NASDAQ: JAN) has acquired an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO). The agreement with LSU Health Shreveport and other intellectual property relating to TSPO's role in treating meth use disorder (MUD) provides JanOne with an opportunity to identify new drugs to enhance TSPO activity.